Morgan Stanley: Orforglipron, an oral weight loss drug, has become a driving force for stock prices, and Eli Lilly can still rise by another 34%
2025-04-18 16:14:22
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.